New, untreated myeloma study using four medicines
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You sign a consent form and truly understand what the study involves
- You are age 65 or older when you sign up
- You have not received any anti-myeloma treatment before (except allowed short steroid or bone-strengthening medicines)
- Your myeloma has symptoms and test results that fit specific “organ damage” or lab/imaging criteria
- Your health status is good enough for study visits (ECOG score 0 to 2)
- Your blood and organ lab tests meet thresholds, including kidney function, liver enzymes, blood counts, and the ability to take medicines by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.